Methoxyphenyl Imidazolines as Potential Activators of p53
The use of p53-MDM2/X inhibitors is a prospective strategy in anti-cancer therapy for tumors with wild type p53 protein. In our study, new low-molecular-weight inhibitors of the p53-mdm2 interaction have been proposed. The two-step synthesis of the imidazoline core with subsequent modifications for...
Main Authors: | Daniil R. Bazanov, Nikolay V. Pervushin, Natalia A. Lozinskaya, Gelina S. Kopeina |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Medical Sciences Forum |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-9992/14/1/100 |
Similar Items
-
Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core
by: Daniil R. Bazanov, et al.
Published: (2022-04-01) -
MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters
by: Kester Mo Henningsen, et al.
Published: (2021-12-01) -
Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
by: Yali Wang, et al.
Published: (2022-06-01) -
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
by: Javier Octavio Mejía-Hernández, et al.
Published: (2022-08-01) -
Therapeutic Strategies to Activate p53
by: Angelo Aguilar, et al.
Published: (2022-12-01)